(Q41877172)
Statements
Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer (English)
N M Corcoran
M Michael
M A Rosenthal
A J Costello
20 July 2010
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference